Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $2.71, but opened at $2.65. Taysha Gene Therapies shares last traded at $2.72, with a volume of 69,852 shares trading hands.

Analyst Ratings Changes

TSHA has been the subject of several research reports. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Canaccord Genuity Group reiterated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Needham & Company LLC boosted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Wednesday, March 20th. Finally, Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Thursday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $6.57.

Taysha Gene Therapies Stock Performance

The company has a market cap of $508.69 million, a PE ratio of -4.06 and a beta of 0.29. The firm's fifty day moving average is $2.28 and its 200 day moving average is $2.12. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital Investment Advisors LLC purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth $32,000. AQR Capital Management LLC acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at about $38,000. Howard Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies during the 4th quarter valued at about $25,000. Maven Securities LTD acquired a new position in Taysha Gene Therapies in the fourth quarter valued at about $34,000. Finally, Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.